AUS
NZ
UK
CA
USA
IND
Orthocell Limited (ASX:OCC) has applied for quotation of 62,894 ordinary fully paid shares issued to its directors on 17 July 2026 as part of director fee compensation under the company's Employee Awards Plan. These shares were issued at AUD 0.75610000 each and had prior shareholder approval at the 2025 annual general meeting. Upon quotation, Orthocell's total issued ordinary fully paid share capital will increase to 272,316,531 shares on the ASX.
Key Points
- Orthocell Limited (OCC) issued 62,894 ordinary fully paid shares to directors as fee remuneration
- Shares issued at AUD 0.75610000 per security on 17 July 2026
- Director fee share issuance approved under the Employee Awards Plan at 2025 annual general meeting
- Total quoted share capital will rise to 272,316,531 ordinary fully paid shares following quotation
- Company holds significant unquoted securities including options and performance rights with various expiry dates and strike prices
Orthocell's Director Fee Shares Issued Under Employee Awards Plan
Orthocell Limited has issued 62,894 ordinary fully paid shares to its directors as part of the Employee Awards Plan, a compensation framework approved by shareholders at the 2025 annual general meeting. This equity-based remuneration aligns directors’ interests with shareholders by providing shares as part of their fee compensation. The shares were issued at AUD 0.75610000 each on 17 July 2026, reflecting market conditions at issuance.
Using share-based compensation for directors is increasingly common among Australian listed companies, fostering alignment between management incentives and long-term shareholder value. Issuing shares instead of cash fees helps conserve company cash while giving directors a direct stake in company performance. Shareholder approval at the 2025 AGM ensured transparency and endorsement of this remuneration approach prior to implementation.
Shareholder Approval and Employee Awards Plan Governance
The share issuance to directors operates within Orthocell’s Employee Awards Plan, formally approved by shareholders at the 2025 annual general meeting. This governance framework ensures transparency and compliance with ASX Listing Rules by enabling structured equity compensation rather than ad hoc share issues. The plan outlines participant eligibility, vesting, and performance conditions, reflecting a considered approach to director and employee equity remuneration.
Such employee awards plans are standard among ASX-listed companies, providing a formal mechanism for issuing shares to eligible participants while maintaining corporate governance standards and regulatory compliance.
Effect on Orthocell’s Share Capital Structure
The issuance of 62,894 shares increases Orthocell’s total quoted ordinary fully paid share capital to 272,316,531 shares. While this increment is modest relative to the overall share base, it may influence future earnings per share calculations and shareholder ownership percentages.
In addition to ordinary shares, Orthocell holds a significant portfolio of unquoted securities, including approximately 24,937,933 options across 13 tranches with expiry dates from April 2027 to October 2028 and strike prices ranging from AUD 0.36 to AUD 1.95. The company also has 3,400,637 unquoted retention rights and 1,947,696 performance rights outstanding, representing potential future dilution if exercised or vested.
Issuance Price and Cash Consideration Details
The director fee shares were issued for cash consideration at AUD 0.75610000 per share on 17 July 2026. This issuance generated cash proceeds for Orthocell while providing directors with equity-based remuneration. The payment of cash consideration indicates directors personally funded their share acquisition, reinforcing alignment of their financial interests with company performance.
This contrasts with some equity compensation arrangements where shares may be issued for nil consideration or subject to vesting conditions, underscoring the directors’ financial commitment to the shares received.
Compliance with ASX Listing Rules and Exception 14
Orthocell’s issuance benefits from ASX Listing Rule 7.2 exception 14, allowing the company to issue these shares without additional shareholder approval under Listing Rule 7.1. This exception applies to securities issued under shareholder-approved employee share schemes, consistent with Orthocell’s Employee Awards Plan approved at the 2025 AGM.
This regulatory provision facilitates ongoing equity compensation without repeated shareholder approvals, reducing administrative burden while maintaining governance oversight through the initial plan approval. Orthocell’s adherence to this framework demonstrates compliance with ASX regulatory requirements.
Company Overview and Market Position
Orthocell Limited (ASX: OCC, ACN 118897135) operates in the biotechnology or medical technology sector. While the update does not detail specific operations or revenue streams, the company’s share capital exceeding 272 million shares and extensive unquoted securities portfolio indicate an established entity with mature corporate governance.
The Employee Awards Plan and equity compensation for directors reflect a structured approach to remuneration. Investors seeking comprehensive insights into Orthocell’s business model, market position, and strategy should consult the company’s latest annual report, financial disclosures, and ASX filings.
Unquoted Securities and Potential Dilution Risks
Orthocell’s unquoted securities portfolio includes 13 option tranches with varying expiry dates and strike prices. Major tranches include 4,000,000 options expiring 29 May 2028 at AUD 0.40, 3,240,000 options expiring 19 April 2027 at AUD 0.36, and 3,000,000 options each expiring 31 October 2027 at AUD 0.67 and 8 March 2028 at AUD 0.40. These options represent contingent equity obligations that could increase the share count upon exercise.
Additionally, 3,400,637 retention rights and 1,947,696 performance rights may convert into ordinary shares upon meeting specified conditions. Collectively, these unquoted securities represent potential dilution of approximately 8 to 9 percent relative to the current quoted share capital of 272.3 million shares, reflecting Orthocell’s historical use of equity-based incentives and capital-raising initiatives.
Regulatory Compliance and Secondary Sale Provisions
The director fee shares comply with secondary sale provisions under sections 707(3) and 1012C(6) of the Corporations Act. Orthocell confirmed that any resale of these shares within 12 months will adhere to applicable secondary sale rules, supported by relevant ASIC instruments or class orders.
These provisions exempt certain employee share scheme issuances from prospectus requirements and disclosure obligations, ensuring directors can sell shares without triggering additional regulatory burdens. Orthocell’s adherence to these statutory frameworks confirms the share issuance aligns with established legal and regulatory standards.
